{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:47:02Z","timestamp":1791953222903,"version":"4.3.4"},"reference-count":42,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Targeting the crosstalk between histone methyltransferases G9a and EZH2 represents a promising strategy for cancer therapy. To improve upon our previously reported dual inhibitor SU08, we rationally designed and synthesized five series (SU, UA, UB, N, and L) of novel G9a\/EZH2 dual inhibitors, incorporating diverse pyridone, urea, and thienopyrimidine moieties, yielding a total of 43 compounds. In vitro enzymatic screening revealed that compound SU101 against both EZH2 (IC50 = 4.08 nM) and G9a (IC50 = 2.92 nM) was comparable to SU08. Western blot analysis confirmed that SU101 and SU103 effectively suppressed both H3K27me3 and H3K9me2 expression in rhabdomyosarcoma RD cells. In cellular antiproliferative assays, SU101 showed the strongest activity (IC50 = 15.33 \u03bcM). Molecular docking and dynamics simulations verified stable binding interactions between SU101 and both target proteins. Pharmacokinetic studies in rats demonstrated that SU101 possesses excellent oral bioavailability (94.3%), moderate plasma protein binding (84.6%), and an acceptable acute toxicity profile (LD50 = 31.02 mg\/kg in mice). Overall, these results suggest that SU101 may serve as a promising lead compound for further optimization and support the continued exploration of dual G9a\/EZH2 inhibitors as a potential therapeutic approach for rhabdomyosarcoma.<\/jats:p>","DOI":"10.3390\/molecules31193446","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:35:59Z","timestamp":1790595359000},"page":"3446","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, Synthesis and Antitumor Activity Evaluation of Novel Dual G9a\/EZH2 Inhibitors"],"prefix":"10.3390","volume":"31","author":[{"given":"Yajie","family":"Shi","sequence":"first","affiliation":[{"name":"College of Pharmacy, Heze University, Heze 274000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China"},{"name":"College of Pharmacy, Jilin Medical University, Changchun 132013, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Heze University, Heze 274000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Heze University, Heze 274000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirui","family":"Li","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Heze University, Heze 274000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haofeng","family":"Li","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Heze University, Heze 274000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Fu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Heze University, Heze 274000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4062\/biomolther.2026.037","article-title":"Molecular Pathogenesis of Vitiligo: Emerging Roles of Epigenetic Regulation","volume":"34","author":"Ahn","year":"2026","journal-title":"Biomol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mogol, A.N., Yoo, J.Y., Eve, A.A., Goel, M., Dutton, D.J., Schane, C.P., Lam, A., Dutta, D., Barnick, B., and Erdogan, E.D. (2026). ACSS2-mediated metabolic-epigenetic crosstalk drives Fulvestrant resistance and represents a novel therapeutic target. npj Breast Cancer, preprint.","DOI":"10.1038\/s41523-026-00987-0"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ejmech.2019.06.072","article-title":"Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents","volume":"179","author":"Cao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ajpath.2021.01.013","article-title":"Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer","volume":"191","author":"Anwar","year":"2021","journal-title":"Am. J. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/0008-5472.CAN-21-2218","article-title":"Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis","volume":"82","author":"Casciello","year":"2022","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.7150\/ijbs.115605","article-title":"Arsenic disrupts H3K9me3 and H3K27me3 balance by biasing PRC2.1 and PRC2.2 activity via PALI1 inhibition in carcinogenesis","volume":"21","author":"Ji","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13148-015-0118-9","article-title":"Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells","volume":"7","author":"Curry","year":"2015","journal-title":"Clin. Epigenet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/1535-7163.MCT-21-0743","article-title":"Dual G9A\/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma","volume":"21","author":"Spiliopoulou","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Flesher, J.L., and Fisher, D.E. (2021). G9a: An Emerging Epigenetic Target for Melanoma Therapy. Epigenomes, 5.","DOI":"10.3390\/epigenomes5040023"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41420-020-00400-0","article-title":"Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis","volume":"7","author":"Ishiguro","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.0c02255","article-title":"Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma","volume":"64","author":"Rabal","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/andr.13604","article-title":"EHMT2\/G9a and EZH2: Epimarkers in testicular germ cell tumors","volume":"13","author":"Flores","year":"2025","journal-title":"Andrology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.molcel.2013.12.005","article-title":"The histone H3 lysine 9 methyltransferases G9a and GLP regulate polycomb repressive complex 2-mediated gene silencing","volume":"53","author":"Mozzetta","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1016\/j.molcel.2022.11.010","article-title":"PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing","volume":"82","author":"Fong","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1080\/17568919.2024.2380243","article-title":"Dual-target EZH2 inhibitor: Latest advances in medicinal chemistry","volume":"16","author":"Wei","year":"2024","journal-title":"Future Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41419-017-0120-6","article-title":"Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN\/AKT signaling pathway","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.7150\/jca.48310","article-title":"EHMT2 inhibitor BIX-01294 induces endoplasmic reticulum stress mediated apoptosis and autophagy in diffuse large B-cell lymphoma cells","volume":"12","author":"Xu","year":"2021","journal-title":"J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1021\/acs.jmedchem.3c00003","article-title":"Discovery of Dual Lysine Methyltransferase G9a and EZH2 Inhibitors with In Vivo Efficacy against Malignant Rhabdoid Tumor","volume":"66","author":"Shi","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"113714","DOI":"10.1016\/j.celrep.2024.113714","article-title":"EZH2\/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4\/ERK\/c-Myc signaling axis","volume":"43","author":"Zhang","year":"2024","journal-title":"Cell Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107314","DOI":"10.1016\/j.bioorg.2024.107314","article-title":"Bioisosteric replacement strategy leads to novel DNA gyrase B inhibitors with improved potencies and properties","volume":"147","author":"Xue","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_21","unstructured":"Paquette, L.E. (1995). Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1039\/C7MD00052A","article-title":"Histone lysine methyltransferase structure activity relationships that allow for segregation of G9a inhibition and anti-Plasmodium activity","volume":"8","author":"Sundriyal","year":"2017","journal-title":"MedChemComm"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/00397911.2018.1439173","article-title":"Facile and efficient synthesis of quinazoline-2,4(1H, 3H)-diones through sequential hydrogenation condensation","volume":"48","author":"Wang","year":"2018","journal-title":"Synth. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1021\/acs.orglett.2c00122","article-title":"Room Temperature Cu-Catalyzed N-Arylation of Oxazolidinones and Amides with (Hetero)Aryl Iodides","volume":"24","author":"Bhunia","year":"2022","journal-title":"Org. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11942","DOI":"10.1021\/jacs.5b08411","article-title":"CuI\/Oxalic Diamide Catalyzed Coupling Reaction of (Hetero)Aryl Chlorides and Amines","volume":"137","author":"Zhou","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cclet.2010.12.018","article-title":"An efficient method for the N-arylation of phenylurea via copper catalyzed amidation","volume":"22","author":"Gavade","year":"2011","journal-title":"Chin. Chem. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1016\/j.bmcl.2009.08.040","article-title":"Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor","volume":"19","author":"Bedford","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejmech.2010.10.016","article-title":"The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes","volume":"46","author":"Deng","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"129726","DOI":"10.1016\/j.bmcl.2024.129726","article-title":"Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors","volume":"105","author":"Cai","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"116524","DOI":"10.1016\/j.bmc.2021.116524","article-title":"Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents","volume":"53","author":"Zheng","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.bmc.2017.06.021","article-title":"Structure-activity relationship studies of G9a-like protein (GLP) inhibitors","volume":"25","author":"Xiong","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.jmedchem.7b01375","article-title":"Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)","volume":"61","author":"Kung","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0272-0590(85)90059-4","article-title":"An up-and-down procedure for acute toxicity testing","volume":"5","author":"Bruce","year":"1985","journal-title":"Fundam. Appl. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1021\/acscombsci.0c00077","article-title":"Optimization of High-Throughput Methyltransferase Assays for the Discovery of Small Molecule Inhibitors","volume":"22","author":"Dong","year":"2020","journal-title":"ACS Comb. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"pdb-prot095505","DOI":"10.1101\/pdb.prot095505","article-title":"Analysis of Cell Viability by the MTT Assay","volume":"2018","author":"Kumar","year":"2018","journal-title":"Cold Spring Harb. Protoc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1017\/S0033583525000034","article-title":"Protein Data Bank (PDB): Fifty-three years young and having a transformative impact on science and society","volume":"58","author":"Berman","year":"2025","journal-title":"Q. Rev. Biophys."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"115839","DOI":"10.1016\/j.addr.2026.115839","article-title":"Molecular Modeling and machine learning for predicting high-concentration antibody viscosity","volume":"233","author":"Baizhigitova","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1080\/07391102.2018.1491422","article-title":"Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: A molecular dynamics study","volume":"37","author":"Hsieh","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1021\/acs.jctc.3c00714","article-title":"Efficient Empirical Valence Bond Simulations with GROMACS","volume":"19","author":"Oanca","year":"2023","journal-title":"J. Chem. Theory Comput."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/s41598-023-50964-x","article-title":"A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of EZH2 inhibition","volume":"14","author":"Falkenstern","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"030901","DOI":"10.1063\/5.0227517","article-title":"The evolution of the Amber additive protein force field: History, current status, and future","volume":"162","author":"Wang","year":"2025","journal-title":"J. Chem. Phys."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/19\/3446\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:10:24Z","timestamp":1791951024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/19\/3446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":42,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["molecules31193446"],"URL":"https:\/\/doi.org\/10.3390\/molecules31193446","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]}}}